Condition: Metastatic Non-small Cell Lung Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
This description comes directly from the study's public registry record.
Helena Yu, MD · 646-608-2252 · yuh@mskcc.org
Gregory Riely, MD, PhD · 646-608-3913
Always discuss trial participation with your own doctor first.
| UC Davis Cancer Center (Data Collection Only) | Sacramento, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Active Not Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| John Hopkins Medical Center | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital (Data Collection Only) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Hackensack Meridian Health | Hackensack, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Commack (Limited protocol activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited protocol activities) | Harrison, New York, United States | Recruiting |
| New York University | New York, New York, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04410796